ofatumumab   Click here for help

GtoPdb Ligand ID: 6778

Synonyms: Arzerra® | GSK 1841157 | GSK1841157 | humax-CD20 | Kesimpta® (subcutaneous) | OMB-157 | OMB157
Approved drug Immunopharmacology Ligand
ofatumumab is an approved drug (FDA (2009), EMA (2010))
Compound class: Antibody
Comment: Ofatumumab is a type I anti-CD20 monoclonal, designed to target surface CD20 on B-lymphocytes.
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: ofatumumab

Immunopharmacology Comments
Binding of ofatumumab to the membrane-proximal epitope of CD20 induces recruitment and activation of the complement pathway at the cell surface. This leads to complement-dependent cytotoxicity which results in lysis of tumour cells.
Immunopharmacology Disease
Disease X-Refs Comment References
Chronic lymphocytic leukemia Disease Ontology: DOID:1040
OMIM: 151400
Orphanet: ORPHA67038
Approved drug for some CLL patients.